Your cart is currently empty!
IGF-LR3 0.1MG (100MCG)
IGF-1 LR3 IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of insulin-like growth factor-1 with an arginine substitution at position 3 and an extended N-terminal sequence, resulting in reduced binding to IGF-binding proteins and prolonged half-life. Preclinical studies in cell cultures and animal models indicate that IGF-1 LR3 stimulates cell proliferation, promotes…
5 in stock
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of insulin-like growth factor-1 with an arginine substitution at position 3 and an extended N-terminal sequence, resulting in reduced binding to IGF-binding proteins and prolonged half-life. Preclinical studies in cell cultures and animal models indicate that IGF-1 LR3 stimulates cell proliferation, promotes muscle satellite cell activation, and supports tissue growth through enhanced IGF-1 receptor signaling.[1][2]
Key Research Areas
- Muscle Cell Proliferation & Hyperplasia – In vitro satellite cell cultures and rodent models show IGF-1 LR3 promotes myoblast proliferation and differentiation, leading to increased muscle cell number (hyperplasia) and enhanced regenerative capacity in injury models.[3][4]
- Tissue Growth & Organ-Specific Effects – Preclinical investigations in fetal sheep and other animal models demonstrate IGF-1 LR3 infusion stimulates organ growth, increases skeletal muscle mass, and supports anabolic processes in growth-restricted or normal development paradigms.[5][6]
- Metabolic & Recovery Pathways – Animal studies suggest IGF-1 LR3 modulates protein synthesis, reduces protein degradation, and influences nutrient partitioning in models of muscle maintenance and repair.[7][8]
Product Specifications
| CAS Number | 143045-27-6 |
| Molecular Formula | C400H625N111O115S9 |
| Molar Mass | 9117.5 g/mol |
| Sequence | MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA |
| Synonyms | Long R3 IGF-1, LR3 IGF-1, Long Arginine 3 IGF-1 |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Storage | −20°C (long-term), 2–8°C (reconstituted) |
| Solubility | Bacteriostatic water or sterile saline for reconstitution |
References
- 1. Ballard FJ, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J Endocrinol. 1993. PubMed
- 2. Tomas FM, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. Endocrinology. 1995. PubMed
- 3. Stremming J, et al. Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep. Front Physiol. 2022. PubMed
- 4. Hill RA, et al. Action of long (R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. Domest Anim Endocrinol. 1999. (Protein metabolism data)
- 5. Stremming J, et al. Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Am J Physiol Endocrinol Metab. 2023. PubMed
- 6. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. Am J Physiol Endocrinol Metab. 2024. PubMed
- 7. Kretzschmar C, et al. IGF-1 LR3 and muscle regeneration in animal models. Preclinical data review. 2023. (Regeneration context)
- 8. Tomas FM. Long R3 IGF-I effects on growth and metabolism in animal models. J Endocrinol. 1995. (Metabolic pathways)





